This pathway would be used by retatrutide (Fig
[1] [2] As of 2024, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed medicine in the UK
Conversely, constipation has been shown to persist longer than other GI side effects and is more frequently observed in obesity-focused studies
Medication Review Discuss all your medications with your healthcare provider, particularly if you take SGLT2 inhibitors (which increase urination by design) or diuretics
The GLP-1RAs@NPs-WYRGRL precipitate, which was coated with GLP-1RAs and cross-linked with WYRGRL, was obtained
Current evidence suggests that GLP-1 receptor agonists are not only safe for patients with fatty liver disease but may offer specific hepatic benefits beyond weight loss alone